Coronavirus (COVID-19) Information

 

COVID-19 web information is also available in ChineseVietnamese, Korean and Spanish (click on the language to be taken to the page).


5/5/21 Back to basic precautions to slow the spread

With all metro counties experiencing “high risk” conditions for the spread of COVID-19, it’s more important than ever to practice basic precautions to help keep ourselves and our communities safe. The best way to prevent illness is to avoid exposure to the virus. What can you do to help slow the spread?

The Center for Disease Control recommends you:

If you’ve been fully vaccinated, you may choose to change some of the precautions you are taking. Click here to learn more about keeping yourself and others safe after you’ve been fully vaccinated.  

4/30/21  Multnomah County has released additional information about the safety of the Johnson & Johnson  Covid-19 vaccine, after recently readopting its use. Download the document: in English or in Spanish

3/14/21 Authorized and Recommended Vaccines

As COVID-19 vaccines are authorized and then recommended for use in the United States, it will be important to understand what is known about each vaccine. CDC will provide information on who is and is not recommended to receive each vaccine and what to expect after vaccination, as well as ingredients, safety, and effectiveness.

Currently, three vaccines are authorized and recommended to prevent COVID-19 (click on the name for more info):

Pfizer-BioNTech

Moderna

Johnson & Johnson (Janssen)

Questions and answers on the latest approved COVID-19 vaccine, Johnson & Johnson (J&J).

Who can receive J&J COVID-19 Vaccine?

Like the Moderna and Pfizer Vaccines, the J&J COVID-19 Vaccine is authorized and recommended for persons 18 years of age and older.

How Many does of the J&J COVID-19 Vaccine do patients need?

All people for whom vaccination is indicated should receive 1 dose.

How well does J&J COVID-19 Vaccine prevent COVID-19?

The effectiveness data to support the EUA include an analysis of 39,321 participants in the ongoing randomized, placebo-controlled study being conducted in South Africa, certain countries in South America, Mexico, and the U.S. who did not have evidence of SARS-CoV-2 infection prior to receiving the vaccine. Among these participants, 19,630 received the vaccine and 19,691 received placebo. Overall, among these clinical trial participants, the vaccine was approximately 67% effective in preventing moderate to severe/critical COVID-19 disease occurring at least 14 days after vaccination and 66% effective in preventing moderate to severe/critical disease at least 28 days after vaccination.

Additionally, the vaccine was approximately 77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination.

What information is available about the SARS-CoV-2 strains that caused the cases of COVID-19 in study participants during the clinical trial?

Efficacy of the J&J COVID-19 vaccine demonstrated in the clinical trial reflected protection against several emerging SARS-CoV-2 variants of concern, including the Wuhan-H1 variant D614G (predominant in the United States), the B.1.351 variant (predominant in South Africa), and a P.2 variant (predominant in Brazil).

What information is available about allergic reactions?

In the study that evaluated safety in 43,783 participants (21,895 of whom received the vaccine and 21,888 of whom received saline placebo), hives was reported in five vaccine recipients and 1 placebo recipient in the 7 days following vaccination. In this study, there has been one report of severe hypersensitivity reaction, not classified as anaphylaxis, beginning two days following vaccination with Janssen COVID-19 Vaccine. The event was serious and likely related to vaccination.

In another ongoing clinical study in South Africa, one case of anaphylaxis has been reported following administration of the vaccine.

 

1/2021 Update: Click here to see what we’re doing to keep our community safe during the COVID-19 pandemic

 

9/2020 Update: Click here to view Coronavirus/COVID-19 Questions & Answers

 

3/27/2020: A Letter to the Community from our CEO, Rebecca Ramsay

 

Dear patients, caregivers, family members and community supporters,

 

The last month has been unprecedented, to say the least. As COVID-19 extended its reach, CareOregon and Housecall Providers started preparing for what we knew was coming to the Northwest.

 

Our preparations have focused on how to care for our patients — the most vulnerable targets of the virus — while doing everything in our power to protect both them and staff members who would be going into their homes. At the same time, we heard from our state leaders about the need for social distancing and limits to visitors in facilities. Our biggest concern echoed that of health care communities across the U.S.: lack of available personal protective equipment (PPE) — including masks, gowns, gloves and goggles and/or face shields — which are essential to protect our patients and staff and prevent the spread of COVID-19. We quickly realized that our limited supply required that we temporarily suspend or significantly limit in-person visits across all our programs until we received the amount of PPE necessary to protect our patients, caregivers and staff. Currently, we are still waiting for additional supplies, but they are anticipated shortly. More

Our Commitment

The health, safety and well-being of our patients is our top priority during the outbreak of COVID-19 (coronavirus). Housecall Providers and CareOregon’s clinical leadership have been working to create screening tools and procedures that will help us, as a health care organization, minimize the spread of the disease while we continue to provide home-based medical care to our patients and families.

COVID-19 is a respiratory illness that is thought to spread mainly between people who are in close contact with one another (within about six feet). Symptoms may include fever, cough and shortness of breath.

As a health care provider, we rely on the daily flow of information from the Centers for Disease Control and Prevention (CDC) as they monitor the situation. To learn more about COVID-19 or how the CDC is responding to the outbreak, please click on the following link: cdc.gov/coronavirus/2019-ncov.

Have questions? Want to learn more?

The Center for Disease Control and Prevention (CDC) is monitoring the situation closely. You can learn more here.

You can also call 211 or visit their website at https://www.211info.org/corona-virus for more general information.

The Oregon Health Authority (OHA) has developed a website called Safe + Strong that shares information about COVID-19 in a multilingual way.

OHA has also posted some helpful fact sheets that can be found here:

COVID-19 fact sheet

Prevention fact sheet